HB10887: Protecting Consumer Access to Generic Drugs Act of 2026
- 1Introduced (current step)
- 2Passed One Chamber
- 3Passed Both Chambers
- 4Became Law
Here is how to read this bill
Start with the summary
It says what the bill does in plain language. The official text is one tab over.
Check where it is
The status badge says how far it has gotten. The History tab lists every step.
Follow it
We will email you when it moves. You need a free account.
Tell someone who votes on it
Email or call the sponsor, or find your own representatives, from the actions panel.
Bill information
Summary
To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
Plain-language summary
This bill would ban 'pay-for-delay' deals, where brand-name drug makers pay generic drug makers to delay selling cheaper versions. It also prohibits similar payments involving biological drugs and their cheaper alternatives called biosimilars. These deals currently allow brand-name companies to keep higher prices longer by preventing generic competition. The bill applies to both traditional chemical drugs and newer biological products. It has been introduced in Congress but has not yet advanced to .
AI-generated summary
What can I do?
It's early in the process — messages to the sponsor and your representatives carry the most weight right now.
Contact Your Representatives
Calling or emailing is the most direct way to weigh in — offices tally constituent contacts.
Find Your RepresentativesShare This Bill
Sharing helps others in your district get informed and involved.
HB10887: Protecting Consumer Access to Generic Drugs Act of 2026